MeSH tree: E01.789
Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B-cell lymphoma patients than the widely used International Prognostic Index. By identifying patients ...
Apr 22, 2026
0
1
At the International Society for Heart and Lung Transplantation (ISHLT) 46th Annual Meeting and Scientific Sessions, held from 22–25 April at the Metro Toronto Convention Center in Toronto, ON, Canada, transplant specialists ...
Apr 22, 2026
0
7
Cultures of silence among health care professionals remain a significant threat to patients and health care innovation, according to results from a national survey of more than 3,500 clinicians and health care administrators.
Apr 21, 2026
0
5
Late-breaking results from the Phase III NRG GY019 trial indicate that letrozole monotherapy (L) did not demonstrate noninferiority to paclitaxel/carboplatin followed by letrozole (PC/L) for progression-free survival (PFS) ...
Apr 13, 2026
0
3
Nearly 40% of public-sector physiotherapists want to leave their current job, posing a substantial threat to workforce stability and quality of patient care, University of Otago—Ōtākou Whakaihu Waka research has found. The ...
Apr 9, 2026
0
4
Fragments of tumor DNA circulating in the bloodstream of patients with breast cancer can predict whether they are likely to relapse, especially when samples are taken after the patients have received treatments prior to surgery. ...
Mar 26, 2026
0
9
CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone lymphoma, according to a recent clinical trial published in The Lancet. Marginal zone lymphoma ...
Mar 4, 2026
0
6
When a trauma patient enters the emergency department, their potential for survival often depends on what happens within the first minutes after their arrival. After studying trauma resuscitation teams at UPMC Presbyterian ...
Mar 4, 2026
0
6
Commonly prescribed cardiovascular medications—such as statins, diuretics, and blood pressure drugs—appear to have little or no negative impact on survival among people living with multiple myeloma, according to new international ...
Mar 2, 2026
0
10
Perioperative enfortumab vedotin plus pembrolizumab and surgery lead to significantly better outcomes among patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy compared with surgery ...
Feb 27, 2026
0
7
